TARRYTOWN, N.Y. — February 2, 2026 — Leads & Copy —
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis annual meeting on February 7, 2026. The presentations include new clinical data supporting the efficacy and safety of EYLEA HD® (aflibercept) Injection 8 mg for treating patients with serious retinal diseases.
According to Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron, presentations will highlight the EYLEA HD clinical profile, showcasing its durability while allowing similar efficacy and safety to EYLEA 2 mg, but with fewer injections. The Phase 3 data supporting EYLEA HD approval in RVO, where its durability offers the first every-two-month treatment option, will be presented. Before this, monthly treatment was required with all other anti-VEGF agents.
Data will also be presented from the ELARA trial, supporting EYLEA HD approval as a monthly treatment for the small number of patients who need more frequent treatment. Presentations will show that patients who switched to monthly EYLEA HD from other anti-VEGF agents generally improved their vision, while also achieving better anatomic control.
EYLEA HD was recently approved by the FDA for treating patients with macular edema following retinal vein occlusion (RVO) based on Phase 3 QUASAR trial data. The trial met its primary endpoint at 36 weeks. The treatment is the first every-two-month option for these patients. At Angiogenesis, final, long-term results through the end of the trial (at 64 weeks) will be presented.
Angiogenesis will also mark the first presentation of full primary data from ELARA, a single-arm, Phase 3b trial evaluating EYLEA HD dosed every 4 weeks in previously treated patients with wet age-related macular degeneration (wAMD) or diabetic macular edema (DME). The ELARA trial supported approval of this monthly option for some patients, while also showing that patients who switched to EYLEA HD from other anti-VEGF treatments generally improved their visual acuity while also achieving better anatomic control of retinal swelling.
The most common adverse reactions (≥3%) reported in patients treated with EYLEA HD across approved indications were cataract, conjunctival hemorrhage, corneal epithelium defect, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, retinal hemorrhage, vision blurred, vitreous detachment and vitreous floaters.
Regeneron presentations at Angiogenesis include:
- Correlation of Foveal Invasion with Visual Function at Baseline in the Regeneron SIENNA Geographic Atrophy C5 Inhibitor Trial (Glenn J. Jaffe, 11:20am EST)
- Safety and Efficacy of Aflibercept 8 mg in Patients With nAMD or DME: Primary Results from the Phase 3b ELARA Trial (David M. Brown, 4:45pm EST)
- Aflibercept 8mg in Retinal Vein Occlusion: Final Results from the QUASAR Study* (Varun Chaudhary, 4:55pm EST)
- Safety Profile of Aflibercept 8 mg: A Pooled Analysis of the CANDELA, PULSAR, PHOTON, and QUASAR Trials (John A. Wells, 5:05pm EST)
EYLEA HD was developed to achieve comparable efficacy and safety to EYLEA, but with fewer injections. EYLEA HD is approved in the U.S. to treat patients with wAMD, DME, DR and RVO.
EYLEA HD (known as Eylea™ 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG. Regeneron maintains exclusive rights to EYLEA and EYLEA HD in the U.S. Bayer has licensed the exclusive marketing rights outside of the U.S.
Regeneron is developing new solutions for patients with serious eye diseases, with a research and development program in ophthalmology that includes the Phase 3 SIENNA clinical trial in geographic atrophy, as well as additional novel candidates for uveitis, glaucoma and thyroid eye disease.
EYLEA HD® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) and Macular Edema following Retinal Vein Occlusion (RVO).
Please click here for full Prescribing Information for EYLEA HD and EYLEA.
Regeneron (NASDAQ: REGN) invents, develops and commercializes medicines for people with serious diseases. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
